Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal.
Stephan Busque, John D Scandling, Robert Lowsky...
https://pubmed.ncbi.nlm.nih.gov/31996467/Actively Recruiting
Led by Alice Bertaina · Updated on 2023-07-17
12
Participants Needed
1
Research Sites
104 weeks
Total Duration
Researchers are evaluating a phase 1b2a trial studying sequential alpha-beta depleted hematopoietic stem cell transplantation HSCT and kidney transplantation KT in patients who need a kidney transplant. The goal is to prevent kidney rejection after transplant without lifelong immunosuppression, reducing the risk of chronic rejection and the need for repeated transplants. This trial is for patients with conditions such as SIOD, FSGS, cystinosis, SLE nephritis, or chronic kidney disease stage 4, among others. Participants will undergo one of two conditioning regimens prior to receiving alpha-beta depleted HSCT from a donor. At least three months after HSCT, if donor myeloid engraftment is confirmed and there are no signs of kidney rejection, patients will receive a living donor kidney transplant from the same donor. Pharmacological immunosuppression used for the kidney transplant will be tapered off by day 90 after the transplant if no rejection occurs. The study begins with a safety evaluation in a small group of patients and may expand based on safety and feasibility. During the study, patients will be closely monitored for donor cell engraftment, kidney function, and any signs of graft-versus-host disease GvHD. Researchers will measure how many patients can stop immunosuppression by 90 days after kidney transplant, kidney function at one year, donor chimerism, and any acute or chronic GvHD. Follow-up will include assessments up to five years post-transplant to observe long-term outcomes such as secondary malignancies. Total participation length may extend up to a decade based on study timelines.
CONDITIONS
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Alice Bertaina
Lead Sponsor
California Institute for Regenerative Medicine (CIRM)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | HSCT + Kidney Transplant from Same Donor | Standard Kidney Transplant (Current Practice) |
|---|---|---|
| What it is | A protocol in which patients with advanced kidney disease first receive a stem cell (hematopoietic) transplant from their intended kidney donor to induce immune tolerance, followed several months later by a kidney transplant from the same donor without lifelong immunosuppression. | Standard practice for eligible pediatric and young adult patients with end-stage kidney disease is a kidney transplant from a living (or deceased) donor, managed with long-term immunosuppressive therapy to prevent rejection. |
| Primary use/intended clinical aim | To enable successful kidney transplantation while allowing for the withdrawal of immunosuppressive drugs by achieving stable donor-specific immune tolerance through sequential donor-matched HSCT. | To restore kidney function by transplanting a healthy kidney, with ongoing immunosuppression to prevent rejection for as long as the graft survives. |
| How it is given/performed | Eligible patients first undergo a genetically matched hematopoietic stem cell transplant (with conditioning regimen A or B) from the planned kidney donor. After immune system recovery and confirmed donor cell engraftment, and if criteria are met, the patient receives a kidney transplant from the same donor. The approach uses specific conditioning and cell depletion strategies to enable tolerance. | Transplant candidates with advanced kidney disease receive a donor-matched kidney, typically without prior stem cell procedures. Standard immune-suppressing medication begins before or at the time of surgery and continues indefinitely. |
| Evidence status | Evidence for this protocol comes from small studies and early clinical trials, mostly in selected populations. Tolerance to the kidney graft without maintenance immunosuppression has been achieved in a subset of previous cases, but risks and long-term outcomes are still under investigation. | Decades of published data support kidney transplantation as the treatment of choice for children and young adults with kidney failure, leading to improved survival and quality of life compared to dialysis, though ongoing risk of graft loss and the need for immunosuppression remain. |
| Important limitations | The procedure combines two major transplants in one patient, potentially increasing risk of complications from conditioning, graft-versus-host disease, infection, graft failure, and rare but serious risks. Immune tolerance is not guaranteed for every patient, and the protocol requires closely matched donors and highly selected candidates. | Kidney transplantation with immunosuppression enables long-term graft survival for most pediatric and young adult patients, but still carries risks such as chronic rejection, infection, hypertension, and side effects of prolonged immunosuppression. Immunosuppression is rarely discontinued outside research settings. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 3 months
Participants receive a conditioning regimen including various chemotherapy drugs and radiation prior to undergoing an αβ-depleted hematopoietic stem cell transplant from an HLA-partially matched donor.
Multiple visits during conditioning and transplant period
Duration - Day of transplant plus at least 3 months post-transplant for immunosuppression taper
In participants with successful donor cell engraftment and meeting eligibility criteria post-HSCT, a living donor kidney transplant is performed using the same donor as the HSCT.
1 transplant procedure and approximately weekly visits for 3 months post-transplant
Duration - At least 3 months post-kidney transplant and up to 1 year or longer
Participants are monitored for kidney function, donor chimerism, graft-versus-host disease, and immunosuppression is tapered off if no rejection occurs.
Weekly to monthly visits during follow-up period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Stephan Busque, John D Scandling, Robert Lowsky...
https://pubmed.ncbi.nlm.nih.gov/31996467/T Kawai, D H Sachs, B Sprangers...
https://pubmed.ncbi.nlm.nih.gov/24903438/Vikas R Dharnidharka, Paolo Fiorina, William E Harmon
https://pubmed.ncbi.nlm.nih.gov/25099579/Alice Bertaina, Pietro Merli, Sergio Rutella...
https://pubmed.ncbi.nlm.nih.gov/24869942/Abhijat Kitchlu, Stephanie Dixon, Jade S Dirk...
https://pubmed.ncbi.nlm.nih.gov/30048393/John D Scandling, Stephan Busque, Robert Lowsky...
https://pubmed.ncbi.nlm.nih.gov/29330112/Riko Kelter
https://pubmed.ncbi.nlm.nih.gov/34404344/Tatsuo Kawai, A Benedict Cosimi, Thomas R Spitzer...
https://pubmed.ncbi.nlm.nih.gov/18216355/Fanny Lepeytre, Mourad Dahhou, Xun Zhang...
https://pubmed.ncbi.nlm.nih.gov/28592422/Alice Bertaina, Paul C Grimm, Kenneth Weinberg...
https://pubmed.ncbi.nlm.nih.gov/35704481/Alice Bertaina
Lead Sponsor
California Institute for Regenerative Medicine (CIRM)
Collaborating Sponsor